RARE CANCER    

updates

STAY UP TO DATE on new developments

The New Voices in Science, Engineering and Medicine Program announces its 2021-2023 cohort of 22 early-career leaders from academia, industry, government, and non-profit organizations.

The new members are rising stars in their fields and have been selected through a competitive review process out of nearly 300 applicants.

 

The New Voices program was launched by the National Academies of Sciences, Engineering, and Medicine in 2018 as an initiative to bring diverse perspectives from early-career U.S. leaders to important dialogues around how science, engineering, and medicine are shaping the global future. The program is made possible with support from the Gordon and Betty Moore Foundation. 

Learn more here

No Warrior Left Behind

Cancer Wellness Magazine

by Britt Julious

July 23, 2021

For SHEPHERD Therapeutics founder David Hysong, “rare isn’t rare” is more than just a slogan when it comes to oncology. It is a battle cry rooted in his personal fight against cancer.

 

“We like to think about where we think the world will be in 10 years and then basically make that reality accessible now,” says David Hysong, founder and CEO of SHEPHERD Therapeutics

 

Since founding the company in 2015 and launching its sister organization, SHEPHERD Foundation, Hysong has been on a mission to revolutionize the world of oncology, especially rare cancers. Utilizing a new program, Delve, which matches any cancer (or cancer patient) with the best therapeutics to target their diseases, SHEPHERD aims to leave no patient behind. But SHEPHERD Therapeutics’ mission is more than just noble for Hysong. It’s also personal. 

Learn more here

Inspirational Women in STEM and Tech: Dr. Catharine Young of The SHEPHERD Foundation On The 5 Leadership Lessons She Learned From Her Experience

Authority Magazine

by Penny Bauder

June 24, 2021

As a part of my series about “Lessons From Inspirational Women in STEM and Tech”, I had the pleasure of interviewing Dr. Catharine Young.

Dr. Catharine Young is the former Senior Director of the Biden Cancer Initiative, now serving as Executive Director of the highly impactful SHEPHERD Foundation.

Fresh off the Biden campaign, Catharine was named Executive Director of the SHEPHERD Foundation, a separate vertical of SHEPHERD Therapeutics. SHEPHERD Therapeutics is a force for change in how rare cancers are diagnosed and treated. The SHEPHERD “Rare Isn’t Rare” approach has garnered the attention of big Pharma and oncologists across the globe. In her role as director of the Foundation, Catharine oversees the non-profit arm of SHEPHERD.

Read full article here

SHEPHERD Therapeutics Announces Research Collaboration with National Institutes of Health's (NIH)


SHEPHERD Therapeutics announces its collaboration with the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health. This partnership will identify drugs and drug combinations from NCATS’ annotated compound libraries that may have the potential to significantly improve treatment options and outcomes for patients with adenoid cystic carcinoma, a rare head and neck cancer.

 

Read more here.

SHEPHERD Therapeutics and Oncoheroes Biosciences to Partner for the Discovery, Development and Commercialization of Oncology Therapeutics For Rare Cancers

SHEPHERD Therapeutics announces its partnership with Oncoheroes Biosciences in the discovery, development and commercialization of innovative drug products for rare oncology indications, starting with Oncoheroes’ lead asset, Volasertib.

 

Read more here

RACE for Children Act


As of August 18, 2020, The RACE for Children Act (Research to Accelerate Cures and Equity for Children Act) will be fully implemented. Congratulations to Kids V Cancer and the work of others in driving this change!

 The Race for Children Act now requires all adult cancer therapies in development, whose molecular target is substantially relevant to a pediatric cancer, to be studied in children's cancers as well.

Learn more
here

21st Century Cures 2.0


In April, US Rep. Diana DeGette (D-CO) and Fred Upton (R-MI) released a concept paper for their bipartisan “Cures 2.0.” This legislation builds on the 21st Century Cures Act (P.L. 114-255) passed in 2016, which focused on medical research and new treatments.

Themes that Cures 2.0 will likely focus on include patient engagement in health care decision-making, diversity in clinical trials, and FDA modernization, among others.

Learn more
here

Advancing Access to Precision Medicine Act


Last September, Rep. Eric Swalwell (D-CA) introduced the bipartisan Advancing Access to Precision Medicine Act to push forward use of genetic and genomic testing to improve and save lives.

Learn more
here

TargetCancer Foundation Announces Rare Cancer Precision Medicine Research Initiative


In August, TargetCancer Foundation (TCF) in partnership with Foundation Medicine and academic investigators announced the the initiation of the TCF-001 TRACK (Target Rare Cancer Knowledge) Study. This study will provide precision medicine to rare cancer patients and their treating physicians, right in their own communities. Patients will receive comprehensive genomic profiling of tissue and blood, and resulting reports will be provided to a virtual molecular tumor board, who will recommend treatment options. The study is also incorporating remote consent to break down geographic barriers to participation, and allow patients to both consent and continue to be treated locally.

Learn more
here

Oncoheroes Bioscience Announces FDA Rare Pediatric Disease Designation to to volasertib, an investigational treatment for rhabdomyosarcoma

During childhood cancer awareness month Oncoheroes is delighted to announce that the United States Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPDD) to volasertib, an investigational treatment for rhabdomyosarcoma being developed at Oncoheroes Biosciences.

“This designation marks an important milestone for Oncoheroes as we are now eligible to receive a priority review voucher at the time of marketing approval of volasertib,” announced today Ricardo Garcia, Oncoheroes’ Founder and CEO.

Learn more here